Eritropoyetina, insuficiencia renal crónica y cáncer .. A insuficiência renal crônica (IRC) é uma enfermidade que provoca a perda parcial ou total da função . Métodología de cuantificación de eritropoyetina. Uploaded . La administración de eritropoyetina Beta y muestras de sangre de todos los . IRC Mecanismos. Los riñones sanos producen una hormona llamada eritropoyetina (EPO). La EPO envía una señal al cuerpo para que produzca más células rojas sanguíneas.

Author: Bagar Nikokree
Country: Lesotho
Language: English (Spanish)
Genre: Travel
Published (Last): 21 March 2010
Pages: 22
PDF File Size: 18.56 Mb
ePub File Size: 5.33 Mb
ISBN: 979-6-15807-433-6
Downloads: 5678
Price: Free* [*Free Regsitration Required]
Uploader: Gardale

The utilization of rHuEp changed definitively the treatment and the natural history of anemia in patients with chronic renal insufficiency CRIand now is modifying the treatment of anemia of other non-renal patients as anemia of premature, anemia in onco-hematological illnesses, anemia in human immunodeficiency virus HIV infection, and for reduction of allogenic blood transfusions in surgery.

More information is needed in order to obtain definite conclusions; in the meantime, using the lowest possible dose of erythropoietin seems to be the most prudent approach. In randomized trials, the achievement of normal or nearly normal hemoglobin levels is not associated with improved ne and reduced cardiovascular risk; however the ideal hemoglobin level with the use of erythropoiesis-stimulating agents seems to be problematic.


Si continua navegando, consideramos que acepta su uso. From Monday to Friday from 9 a. New indications for erythropoietin in clinical practice.

There was a problem providing the content you requested

Complexo Hospitalario Universitario Juan Canalejo. Are you a health professional able to prescribe or dispense drugs?

We analyze briefly the clinical indications of rHuEpo and the possible complications secondary to its use. CiteScore measures average citations received per document published. Previous article Next article. Anemia is almost unavoidable in the last stages of chronic kidney disease.

Universidad de Santiago de Compostela. SRJ is a prestige metric based on the idea that not all citations are the same.

Subscriber If you already have your login data, please click here. The journal fully endorses the goals eritropoyetnia updating knowledge and facilitating the acquisition of key developments in internal medicine applied to clinical practice. Although the cause is multi-factorial, the most known is inadequate erythropoietin production. Subscribe to our Newsletter. Continuing navigation will be considered as acceptance of this use.

Anemia has been associated with poor prognosis in patients with eitropoyetina conditions such as cancer, chronic kidney disease and congestive heart failure.

[Anemia in chronic kidney disease].

You can change the settings or obtain more information by clicking here. The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two receding years.


irf Indicaciones de la eritropoyetina recombinante. SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field. Show more Show less. Print Send to a friend Export reference Mendeley Statistics. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal’s impact. To improve our services and products, we use “cookies” own or third parties authorized to show advertising eritropoydtina to client preferences through the analyses of navigation customer behavior.

INSUFICIENCIA RENAL CRONICA-UCI by Oscar Antonio Urrego Rivera on Prezi

Treatment with erythropoiesis-stimulating agents, such as erythropoietin, is a logical strategy that has enabled clinical improvement and reduced transfusion requirements for the patients; however, total correction of anemia with erythropoiesis-stimulating agents has demonstrated an increase in the risk of mortality or cardiovascular complications associated with these agents.

Nine issues are published each year, including mostly originals, reviews and consensus documents. July Pages This item has received. Causas de respuesta ineficaz a la eritropoyetina recombinante.